FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals, namely, to a pharmaceutical composition for the prevention and / or treatment of respiratory distress syndrome (RDS) or other diseases associated with surfactant deficiency or dysfunction, in the form of an aqueous suspension, including: a) 1.02-1.32 mg/ml of a polypeptide analog of the natural surfactant protein SP-C with the sequence SEQ. ID: NO.1; b) 0.136-0.176 mg/ml of a polypeptide analog of the natural surfactant protein SP-B with the sequence SEQ. ID:NO. 2; c) 33.42-43.25 mg/ml of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); d) 33.42-43.25 mg/ml of the sodium salt of 1-palmitoyl-2-oleyl-sn-glycero-3-phosphoglycerin (POPG Na); e) 0.5-3.5 mg/ml buffer agent selected from the tris(hydroxymethyl) hydrochloride group)aminomethane or phosphate buffer; and f) a tonic regulator in an amount sufficient to provide osmolarity from about 250 to about 400 mOsm/l; with the pH being in the range from 6.4 to 7.6; as well as to the use of this composition for the prevention and/or treatment of RDS or other diseases associated with surfactant deficiency or dysfunction.
EFFECT: group of inventions expands the arsenal of tools used for prevention and/or treatment of RDS or other diseases associated with surfactant deficiency or dysfunction.
11 cl, 2 tbl, 3 ex
